Faenza

Hepatocellular carcinoma HCC is a common and deadly form of liver cancer that often develops in a liver damaged by scarring, making treatment difficult. This research is collecting and analyzing real-world patient data to evaluate the safety and effectiveness of new immunotherapy combinations like atezolizumab-bevacizumab and durvalumab-tremelimumab, and to find the best treatment sequences for advanced liver cancer. The study also aims to identify clinical and laboratory markers that predict how patients respond to these treatments to help personalize care. Participants in this observational study are patients with advanced liver cancer who are receiving frontline systemic therapy with atezolizumab-bevacizumab or other immunotherapies. The study collects data from everyday clinical practice without altering treatments. It focuses on new treatment combinations approved in recent years and aims to understand their real-world use and outcomes. The study monitors patients for up to three years from the start of their therapy. During the study, researchers review patient health, treatment responses, and side effects, tracking outcomes like toxicity, progression-free survival, overall survival, response rates, and eligibility for second-line treatments. Safety is monitored throughout the three-year period to provide comprehensive information on how these therapies work outside of clinical trials. This data will help guide future treatment decisions for liver cancer patients.

Researchers are conducting a multicenter, observational study in Italy to collect detailed information on patients with bone metastases. The study aims to establish a national database to better understand clinical and biological factors related to primary tumors and their bone metastases. This research will also evaluate the impact of treatments and care pathways on skeletal events over a period of up to 15 years. Patients with bone metastases from solid tumors will be enrolled in this study and registered in a specialized online database. Each participant will be followed from enrollment until death or until they stop follow-up for other reasons. The study does not involve any experimental treatments but collects comprehensive data on patients conditions and care. Participants will provide informed consent and their medical data will be regularly recorded and analyzed. The study monitors clinical outcomes, skeletal-related events, and the efficiency of treatment pathways. Data collection will continue for up to 15 years, providing long-term insights into bone metastases and patient management.

Primary biliary cholangitis PBC is a rare autoimmune liver disease that causes chronic inflammation of the bile ducts, leading to serious liver damage if untreated. This research aims to create a national database of PBC patients in Italy linked to biological sample storage to improve understanding of the disease, especially in patients who do not respond well to current treatment. The study involves about 60 centers across Italy and focuses on the biology of PBC and disease progression. Participants will have their clinical and laboratory data collected at the start and then annually through electronic case report forms. Biological samples will also be gathered to study patients genes and immune system differences among various PBC subtypes. This observational study collects data from adult PBC patients diagnosed based on established clinical, antibody, or histological criteria. Throughout the 10-year study, researchers will analyze patient phenotypes, responses to ursodeoxycholic acid therapy, factors affecting disease progression, and the safety and effectiveness of new treatments. Participants will be monitored regularly, with their clinical profiles and biological data helping to support future research, clinical care, and drug development efforts for PBC.

Primary sclerosing cholangitis PSC is a rare, chronic liver disease marked by inflammation and scarring of bile ducts, leading to liver failure and increased risk of colorectal and liver cancers. Both children and adults can be affected, with a median survival of 17 years after diagnosis. PSC is a significant cause for liver transplantation in some countries, and it is closely linked to inflammatory bowel disease. This research aims to develop Italys first national PSC patient database linked with biological sample storage to better understand the diseases prevalence and characteristics. This observational study involves recruiting PSC patients across Italy aged 17 and older. Clinical and laboratory data will be collected at baseline and annually using electronic case report forms. Biological samples will also be stored to support research into patient profiles, disease progression, biomarkers, and therapy responses. The study will run for 10 years to assess long-term safety and effectiveness of new treatments and to identify patient subtypes at higher risk. Participants will provide clinical information and biological samples during their involvement. Researchers will monitor disease progression, therapy responses, and safety data over a decade. The main goal is to identify distinct patient subgroups with higher risks and to collect detailed clinical and laboratory data to improve understanding of PSC. This long-term follow-up aims to guide future treatment and management strategies for PSC patients in Italy.